Platinum-based chemotherapy for first-line treatment of metastatic disease is considered standard of care and is recommended by both the National Comprehensive Cancer Center Network® guidelines and the European Society for Medical Oncology guidelines. Preferred regimens include platinum-based chemotherapy with a VEGF inhibitor and/or a PD-1 inhibitor (for PD-L1 positive tumors).
Biomarker testing is recommended for all tumor histology types in order to determine eligibility for pembrolizumab; only patients with PD-L1-positive tumors (CPS ≥ 1) are eligible for treatment with pembrolizumab. Monotherapy with a VEGF inhibitor is not recommended in the first-line recurrent setting owing to inferior response rates compared with combination platinum-based chemotherapy.
Learn more about the treatment of metastatic cervical cancer.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Sarah Ackroyd. Fast Five Quiz: Recurrent/Metastatic Cervical Cancer - Medscape - May 31, 2023.